Background: Dabigatran etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and
systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional
anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions,
and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the
severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to
low levels of individual variation. This review aims to application of Dabigatran etexilate in specific populations.
Methods: Fifty-five papers were included in the review.
Results: We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application
of DE for different clinical populations, and provide clinical guidelines.
Conclusion: When using DE, one should consider the risk of bleeding, age, renal function, drug interactions, and